Top Markets
Coin of the day
Mymetics Corporation Mymetics Corporation

Mymetics Corporation

MYMX
Clasificación en acciones #42815
Mymetics Corporation is a Swiss biotechnology company dedicated to the research... Mymetics Corporation is a Swiss biotechnology company dedicated to the research and development of vaccines aimed at preventing infectious and debilitating diseases. Its robust pipeline features several promising vaccine candidates, including those for HIV-1/AIDS, COVID-19, intranasal influenza, respiratory syncytial virus (RSV), malaria, and chikungunya. The company actively collaborates with leading institutions such as the Texas Biomedical Research Institute, the PATH Malaria Vaccine Initiative, and the National Institute of Allergy and Infectious Diseases' Laboratory of Malaria Immunology and Vaccinology, focusing on the development and production of virosome-based vaccine formulations for a malaria transmission-blocking agent. Additionally, Mymetics works with Sanofi Pasteur Biologics, LLC to assess the immunogenicity of influenza vaccines. Founded in 1990, the company was formerly known as ICHOR Corporation, adopting its current name in July 2001, and maintains its base of operations in Epalinges, Switzerland.
Precio por acción
$0.0003
Última sincronización: 2026-08-11
Capitalización bursátil
$46.00
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
CH
Comercio Mymetics Corporation (MYMX)

Categoría

Ganancias de Mymetics Corporation (MYMX)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Mymetics Corporation, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Mymetics Corporation desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$5.27B -
US
$1.95B -
NL
- -
CH
$3.01B -
BE
- -
KR